Group 3/13 Element Organic Compounds TRIZ Cases
- Yttrium Complex Synthesis Using Controlled Trihalide Adducts
A yttrium trihalide adduct and cyclopentadienyl compound improve conversion and yield while limiting waste from excess reagents.
- Boron-Containing Heteroaromatic Compounds for Solution Processing
The compounds address costly conventional deposition by enabling solution-processed OLED layers while maintaining performance and extending device lifespan.
- Chiral Pyrrole Derivative Synthesis for Selective TLR7/8 Inhibition
A four-step route uses chiral-amine resolution to produce high-enantiomeric-excess pyrrole derivatives for selective TLR7/8 inhibition.
- 5-Position BODIPY Fluorophores for Low-Concentration Zinc Imaging
Modifying the BODIPY 5-position enables nanomolar zinc detection at lower probe concentrations without toxic protecting-group hydrolysis.
- Aluminum Precursor Compounds for Consistent ALD Growth-Per-Cycle Control
Learn how new aluminum precursor compounds keep ALD growth-per-cycle consistent across temperature changes for precise ultrathin film control.
- Fused Polycyclic Emitters for Efficient Organic Electroluminescence
Fused polycyclic compounds use delayed fluorescence in emission layers to improve luminous efficiency while supporting lower voltage and longer service life.
- Aqueous Radiolabeled Aryl Compound Production for Rapid Formulation
An aqueous oxidation step replaces organic solvents and toxic reagents, supporting rapid, high-yield radiolabeling for immediate formulation.
- Boron-Containing Organic Compounds for Efficient Light Emission
Boron-containing organic compounds with kISC/kRISC ≤ 10 improve exciton conversion, luminescence efficiency, and light-emitting device lifespan.
- OLED Emission Layers with Condensed Cyclic Compounds for Low-Stokes Shift
Combining condensed cyclic compounds with hole transport materials addresses the trade-off between light efficiency and structural stability.
- Benzopyrimidine Compounds Balancing KRASG12D Potency and Oral Bioavailability
Benzopyrimidine compounds target KRASG12D and downstream signaling while structural changes balance tumor-cell inhibition with oral bioavailability.